Separating the wheat from the chaff: essential information in therapeutics Roser LlopMontse BoschJoan-Ramon Laporte Editorial 21 October 2011 Pages: 335 - 337
Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children M. ViljoenM. O. KarlssonM. Rheeders Clinical Trial 06 November 2011 Pages: 339 - 347
A case series of individuals with analytically confirmed acute diphenyl-2-pyrrolidinemethanol (D2PM) toxicity David M. WoodMalgorzata PuchnarewiczPaul I. Dargan Pharmacodynamics 29 October 2011 Pages: 349 - 353
Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers Robert SchmouderSam HariryOlivier J. David Pharmacodynamics 10 November 2011 Pages: 355 - 362
Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19 J. J. SwenT. van der StraatenH.-J. Guchelaar Pharmacogenetics Open access 08 October 2011 Pages: 363 - 370
Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide Violetta DziedziejkoMateusz KurzawskiAndrzej Pawlik Pharmacogenetics Open access 14 October 2011 Pages: 371 - 377
Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia Patchva DorababuNarayana NageshRaghunadharao Digumarti Pharmacogenetics 19 October 2011 Pages: 379 - 387
Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients Nasir Ali AfsarMike UferIngolf Cascorbi Pharmacogenetics 20 October 2011 Pages: 389 - 395
Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia Irena LoryanMarja LindqvistMagnus Ingelman-Sundberg Pharmacokinetics and Disposition 18 October 2011 Pages: 397 - 406
Omeprazole limited sampling strategies to predict area under the concentration–time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping Eileen B. LawsonJerry C. WuJoseph D. Ma Pharmacokinetics and Disposition 19 October 2011 Pages: 407 - 413
Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients Samir K. GuptaBhavna KantesariaPaul Glue Pharmacokinetics and Disposition 27 October 2011 Pages: 415 - 418
Pharmacokinetics of the local anesthetic ropivacaine after transversus abdominis plane block in healthy volunteers D. LatzkeP. MarhoferM. Zeitlinger Pharmacokinetics and Disposition 27 October 2011 Pages: 419 - 425
Patterns, predictors and preventability of adverse drug reactions in the coronary care unit of a tertiary care hospital Padmini DeviDeepak Y. KamathBrendan Dias Pharmacoepidemiology and Prescription 19 October 2011 Pages: 427 - 433
Risk of caffeine toxicity associated with the use of ‘legal highs’ (novel psychoactive substances) Susannah DaviesTerry LeeDavid M. Wood Pharmacoepidemiology and Prescription 29 October 2011 Pages: 435 - 439
Treatments for relapsing–remitting multiple sclerosis: summarising current information by network meta-analysis Fabiola Del SantoDario MarateaAndrea Messori Short Communication 05 November 2011 Pages: 441 - 448
Amiodarone-induced acute hepatotoxicity Usha RaoAjit Agarwal Letter to the Editors 12 October 2011 Pages: 449 - 450
Aspiration of alendronic acid leading to localized bronchiectasis Gordon I. A. MacDonaldGraeme P. CurrieDavid M. Reid Letter to the Editors 19 October 2011 Pages: 451 - 452
